There are some risk stratifications, such as activated B-cell (ABC) origin, BCL2/MYC double-expression, and high International Prognostic Index (IPI) score (3, 4), that are associated with poor prognosis, aggressive disease behavior, or resistance to R-CHOP in DLBCL patients. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.